Last reviewed · How we verify
Chemotherapy/Radiation
Chemotherapy/Radiation is a Cytotoxic chemotherapy and ionizing radiation Small molecule drug developed by Hamilton Health Sciences Corporation. It is currently in Phase 3 development for Various solid tumors and hematologic malignancies (specific indication dependent on trial protocol). Also known as: Group 1.
Chemotherapy and radiation therapy work by damaging cancer cell DNA and triggering cell death, while radiation uses high-energy particles or waves to destroy tumors.
Chemotherapy and radiation therapy work by damaging cancer cell DNA and triggering cell death, while radiation uses high-energy particles or waves to destroy tumors. Used for Various solid tumors and hematologic malignancies (specific indication dependent on trial protocol).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Chemotherapy/Radiation |
|---|---|
| Also known as | Group 1 |
| Sponsor | Hamilton Health Sciences Corporation |
| Drug class | Cytotoxic chemotherapy and ionizing radiation |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Chemotherapy drugs interfere with cell division and DNA replication, causing cancer cells to die or stop proliferating. Radiation therapy delivers targeted high-energy radiation to tumor sites, causing direct DNA damage and cell death. Both modalities are often used in combination to maximize tumor destruction while managing systemic toxicity.
Approved indications
- Various solid tumors and hematologic malignancies (specific indication dependent on trial protocol)
Common side effects
- Nausea and vomiting
- Myelosuppression (bone marrow suppression)
- Alopecia (hair loss)
- Mucositis
- Fatigue
- Radiation dermatitis
- Secondary malignancy risk
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Hyperpolarized Imaging in Diagnosing Participants With Glioma (PHASE1)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer (PHASE1)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy/Radiation CI brief — competitive landscape report
- Chemotherapy/Radiation updates RSS · CI watch RSS
- Hamilton Health Sciences Corporation portfolio CI
Frequently asked questions about Chemotherapy/Radiation
What is Chemotherapy/Radiation?
How does Chemotherapy/Radiation work?
What is Chemotherapy/Radiation used for?
Who makes Chemotherapy/Radiation?
Is Chemotherapy/Radiation also known as anything else?
What drug class is Chemotherapy/Radiation in?
What development phase is Chemotherapy/Radiation in?
What are the side effects of Chemotherapy/Radiation?
Related
- Drug class: All Cytotoxic chemotherapy and ionizing radiation drugs
- Manufacturer: Hamilton Health Sciences Corporation — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Various solid tumors and hematologic malignancies (specific indication dependent on trial protocol)
- Also known as: Group 1
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing